These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 34125951)

  • 1. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
    Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
    Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
    Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
    Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
    JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
    Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
    J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.
    Choi J; Kim KH; Kim HS; Yoon HS; Kim JH; Kim JW; Lee YS; Choi SY; Chang IH; Ko YH; Song W; Jeong BC; Nam JK
    Investig Clin Urol; 2024 May; 65(3):248-255. PubMed ID: 38714515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013776. PubMed ID: 34850382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
    Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
    BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.